OCV

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Ozette Technologies focuses on digitizing biological data through machine learning to provide comprehensive insights into the human immune system. By leveraging a single-cell immune monitoring platform, the company enhances the discovery and annotation of immune cells, facilitating a deeper understanding of immune responses in both health and disease. Its AI-driven computational analysis technology supports scientists and healthcare providers in developing novel therapies and diagnostics, ultimately aiming to improve patient outcomes. Through its innovative approach, Ozette accelerates the advancement of therapeutic solutions by streamlining the analysis of immune data.

Ockam Inc. is a provider of a serverless platform designed for secure Internet-of-Things (IoT) development. Founded in 2017 and headquartered in San Francisco, California, the company offers tools that enable the interconnection of hardware with software services, facilitating secure information exchange among connected systems. Ockam's platform manages identities, cryptographic keys, and credentials for devices and services while optimizing connectivity and messaging. It simplifies the development process by eliminating the complexities of system administration, such as managing IP backlogs and setting up public APIs. The platform is open-source, secure-by-design, and built in Rust, allowing for robust end-to-end encryption, key management, and mutual authentication. Ockam connects application developers, system integrators, hardware engineers, and cloud service product managers, providing a cohesive environment for building trustworthy applications across diverse networks.

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders that involve neuronal imbalance. The company is advancing several lead product candidates, including PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is developing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy. The company also has a program for treating KCNT1 gain-of-function epilepsy. Established in 2015 and based in Cambridge, Massachusetts, Praxis collaborates with other organizations through various agreements to enhance its research and development efforts.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional location in Tel Aviv, Israel, SafeBreach offers a platform that enables organizations to proactively assess their security posture. The platform utilizes a comprehensive Hacker's Playbook, which includes real-world breach methods, to simulate potential attacks across various network segments, cloud environments, and endpoints. By mimicking the tactics of virtual hackers, SafeBreach helps businesses identify vulnerabilities and improve their security controls before actual breaches occur. The platform integrates seamlessly with security information and event management systems, ticketing systems, and automation vendors, allowing for enhanced incident response and remediation. Funded by notable investors, SafeBreach continues to innovate in the field of cybersecurity, providing vital insights to strengthen enterprise defenses against evolving threats.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Figure8 Inc. is a New York-based company that operates a recreational facility focused on frozen dessert-themed attractions, games, and crafts. Founded in 2016 by Manish Vora and Maryellis Bunn, Figure8 is dedicated to creating immersive experiences that foster connections and creativity. The company emphasizes the importance of imagination and aims to enhance relationships with both people and places through its offerings.

Ossio is an orthopedic fixation company dedicated to enhancing the orthopedic experience for patients, healthcare providers, and payors. Established in 2014, the company focuses on developing innovative alternatives to traditional metal implants in the orthopedic fixation market, which is valued at over $10 billion. Their flagship product, OSSIOfiber, utilizes Intelligent Bone Regeneration Technology, offering a biocomposite material that is designed to support the natural healing process. This breakthrough platform allows for secure fixation while enabling the body to regenerate bone tissue, effectively replacing the implant without leaving any permanent material behind. Ossio's technology addresses the limitations of conventional bio-resorbable materials, providing the necessary mechanical strength for easy insertion and stable fixation, while promoting better healing outcomes for patients with orthopedic disorders.

Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.

Orca AI is a maritime technology company founded in 2018 by Navy veterans, based in the United States. The company specializes in a software solution that leverages artificial intelligence and computer vision to enhance the operational safety, efficiency, and sustainability of shipping companies. Its platform focuses on managing vessel data to detect, analyze, and alert users to hazardous scenarios in waterways and deep waters. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed, earning the trust of major industry players across various shipping segments. The company's system aims to reduce collisions and prevent human error, thereby enabling crews to make informed decisions in critical situations. Orca AI has raised $38 million in funding from venture capitalists in the US, UK, and Israel and has a workforce of 80 employees across offices in London, Athens, Singapore, and Tel Aviv.